KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC

May 29-June 2, 2015; Chicago, Illinois
In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.
Format: Microsoft PowerPoint (.ppt)
File Size: 423 KB
Released: June 1, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

Matthew Gubens, MD, MS, provides expert insight on frontline combination regimens using immunotherapy in advanced NSCLC.

Matthew Gubens, MD, MS Released: December 30, 2019

Download this PDF resource for patients with advanced NSCLC receiving immune checkpoint inhibitor therapy, including information on what to expect and how to actively participate in their care.

Released: December 12, 2019

CME-certified Webcast of a CCO symposium at CHEST 2019 featuring expert perspectives on optimal integration of immunotherapy into stage III NSCLC care using a multidisciplinary approach

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit US Physicians: maximum of 1.0 Medical Knowledge MOC point(s) Released: November 20, 2019 Expiration: November 19, 2020

In this slideset, experts provide insights on immunotherapy use for stage III NSCLC today and emerging developments in this setting and earlier stages of NSCLC.

Roy S. Herbst, MD, PhD Melissa L. Johnson, MD Released: November 8, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?